COMMUNIQUÉS West-GlobeNewswire

-
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
05/03/2024 -
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
05/03/2024 -
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
05/03/2024 -
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
05/03/2024 -
PetVivo Holdings, Inc. Commences Trading on Upstream Under PETV
05/03/2024 -
Allyx Therapeutics Announces Expansion into Parkinson’s Disease Clinical Research with Lead Compound ALX-001 Following IND Acceptance
05/03/2024 -
SensaSure Technologies and Verde Bio Holdings File Registration Statement for Previously Announced Merger
05/03/2024 -
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
05/03/2024 -
Immutep Announces First Clinical Data from 90mg Dosing of Efti
05/03/2024 -
Replimune to Present at Three Upcoming Investor Conferences
05/03/2024 -
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
05/03/2024 -
Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract
05/03/2024 -
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results
05/03/2024 -
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
05/03/2024 -
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
05/03/2024 -
Major shareholder announcement – AIM International Mutual Funds
05/03/2024 -
RadNet, Inc. to Present at the 44th Annual Cowen & Company Healthcare Conference on Wednesday, March 6th
05/03/2024 -
Major shareholder announcement - Invesco Ltd.
05/03/2024 -
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
05/03/2024
Pages